U.K.-based trial services company Ergomed has penned a deal to buy PSR Group BV, a specialist orphan drug CRO, as it adds to its offerings.

Biopharma executives share how they manage outsourcing relationships at this year's Drug Development Forum.

A recent study by the Tufts Center for the Study of Drug Development found that EDC systems still aren't efficiently accelerating clinical trials.

Indivumed and Helomics have teamed up to advance research in personalized cancer treatments.

Looking to boost its drug offerings, U.K. CRO Clinigen has paid £150.3 million (around $200 million) to buy out Quantum Pharma.

Parexel has joined forces with the Osaka International Cancer Institute to help “drive greater efficiencies” across trials in Japan.

Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.

U.S. oncology specialist Cancer Genetics will pay $12 million to buy out Australian CRO vivoPharm as it looks to bolster its offerings.